Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras
Patients To Start Receiving The Drug In The Next Few Weeks
Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.